These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

490 related articles for article (PubMed ID: 19061836)

  • 1. Distinct thresholds govern Myc's biological output in vivo.
    Murphy DJ; Junttila MR; Pouyet L; Karnezis A; Shchors K; Bui DA; Brown-Swigart L; Johnson L; Evan GI
    Cancer Cell; 2008 Dec; 14(6):447-57. PubMed ID: 19061836
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Developmental context determines latency of MYC-induced tumorigenesis.
    Beer S; Zetterberg A; Ihrie RA; McTaggart RA; Yang Q; Bradon N; Arvanitis C; Attardi LD; Feng S; Ruebner B; Cardiff RD; Felsher DW
    PLoS Biol; 2004 Nov; 2(11):e332. PubMed ID: 15455033
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The ARF tumor suppressor: keeping Myc on a leash.
    Gregory MA; Qi Y; Hann SR
    Cell Cycle; 2005 Feb; 4(2):249-52. PubMed ID: 15655352
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Egr1 mediates p53-independent c-Myc-induced apoptosis via a noncanonical ARF-dependent transcriptional mechanism.
    Boone DN; Qi Y; Li Z; Hann SR
    Proc Natl Acad Sci U S A; 2011 Jan; 108(2):632-7. PubMed ID: 21187408
    [TBL] [Abstract][Full Text] [Related]  

  • 5. p19ARF directly and differentially controls the functions of c-Myc independently of p53.
    Qi Y; Gregory MA; Li Z; Brousal JP; West K; Hann SR
    Nature; 2004 Oct; 431(7009):712-7. PubMed ID: 15361884
    [TBL] [Abstract][Full Text] [Related]  

  • 6. c-Myc augments gamma irradiation-induced apoptosis by suppressing Bcl-XL.
    Maclean KH; Keller UB; Rodriguez-Galindo C; Nilsson JA; Cleveland JL
    Mol Cell Biol; 2003 Oct; 23(20):7256-70. PubMed ID: 14517295
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Oncogenes and the DNA damage response: Myc and E2F1 engage the ATM signaling pathway to activate p53 and induce apoptosis.
    Hong S; Pusapati RV; Powers JT; Johnson DG
    Cell Cycle; 2006 Apr; 5(8):801-3. PubMed ID: 16582589
    [TBL] [Abstract][Full Text] [Related]  

  • 8. MYC leads the way.
    Venkateswaran N; Conacci-Sorrell M
    Small GTPases; 2020 Mar; 11(2):86-94. PubMed ID: 29173017
    [TBL] [Abstract][Full Text] [Related]  

  • 9. MYC, Metabolism, and Cancer.
    Stine ZE; Walton ZE; Altman BJ; Hsieh AL; Dang CV
    Cancer Discov; 2015 Oct; 5(10):1024-39. PubMed ID: 26382145
    [TBL] [Abstract][Full Text] [Related]  

  • 10. MYC-driven malignant transformation of mature murine B cells requires inhibition of both intrinsic apoptosis and p53 activity.
    Högstrand K; Grandien A
    Eur J Immunol; 2019 Mar; 49(3):375-385. PubMed ID: 30281155
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Oncogenic cooperation between H-Twist and N-Myc overrides failsafe programs in cancer cells.
    Valsesia-Wittmann S; Magdeleine M; Dupasquier S; Garin E; Jallas AC; Combaret V; Krause A; Leissner P; Puisieux A
    Cancer Cell; 2004 Dec; 6(6):625-30. PubMed ID: 15607966
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Bax loss impairs Myc-induced apoptosis and circumvents the selection of p53 mutations during Myc-mediated lymphomagenesis.
    Eischen CM; Roussel MF; Korsmeyer SJ; Cleveland JL
    Mol Cell Biol; 2001 Nov; 21(22):7653-62. PubMed ID: 11604501
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Oncogenic c-Myc-induced lymphomagenesis is inhibited non-redundantly by the p19Arf-Mdm2-p53 and RP-Mdm2-p53 pathways.
    Meng X; Carlson NR; Dong J; Zhang Y
    Oncogene; 2015 Nov; 34(46):5709-17. PubMed ID: 25823025
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The role of senescence and prosurvival signaling in controlling the oncogenic activity of FGFR2 mutants associated with cancer and birth defects.
    Ota S; Zhou ZQ; Link JM; Hurlin PJ
    Hum Mol Genet; 2009 Jul; 18(14):2609-21. PubMed ID: 19403560
    [TBL] [Abstract][Full Text] [Related]  

  • 15. MYC and tumor metabolism: chicken and egg.
    Dejure FR; Eilers M
    EMBO J; 2017 Dec; 36(23):3409-3420. PubMed ID: 29127156
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Regulation of the Arf tumor suppressor in Emicro-Myc transgenic mice: longitudinal study of Myc-induced lymphomagenesis.
    Bertwistle D; Sherr CJ
    Blood; 2007 Jan; 109(2):792-4. PubMed ID: 16968893
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Collaboration of MYC and RUNX2 in lymphoma simulates T-cell receptor signaling and attenuates p53 pathway activity.
    Hay J; Gilroy K; Huser C; Kilbey A; Mcdonald A; MacCallum A; Holroyd A; Cameron E; Neil JC
    J Cell Biochem; 2019 Oct; 120(10):18332-18345. PubMed ID: 31257681
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Targeting ornithine decarboxylase in Myc-induced lymphomagenesis prevents tumor formation.
    Nilsson JA; Keller UB; Baudino TA; Yang C; Norton S; Old JA; Nilsson LM; Neale G; Kramer DL; Porter CW; Cleveland JL
    Cancer Cell; 2005 May; 7(5):433-44. PubMed ID: 15894264
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A non-transgenic mouse model for B-cell lymphoma: in vivo infection of p53-null bone marrow progenitors by a Myc retrovirus is sufficient for tumorigenesis.
    Yu D; Thomas-Tikhonenko A
    Oncogene; 2002 Mar; 21(12):1922-7. PubMed ID: 11896625
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Differential effects on ARF stability by normal versus oncogenic levels of c-Myc expression.
    Chen D; Kon N; Zhong J; Zhang P; Yu L; Gu W
    Mol Cell; 2013 Jul; 51(1):46-56. PubMed ID: 23747016
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 25.